MaxCyte, Inc. (LON:MXCT – Get Free Report)’s share price crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 298.81 ($3.88) and traded as low as GBX 273 ($3.54). MaxCyte shares last traded at GBX 279 ($3.62), with a volume of 2,555 shares.
MaxCyte Stock Up 1.5 %
The company has a market cap of £293.20 million, a P/E ratio of -1,073.08 and a beta of 1.13. The company has a debt-to-equity ratio of 8.37, a current ratio of 14.31 and a quick ratio of 14.38. The stock has a fifty day moving average price of GBX 298.81 and a two-hundred day moving average price of GBX 326.08.
Insiders Place Their Bets
In related news, insider Stan Erck sold 47,689 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of GBX 388 ($5.03), for a total transaction of £185,033.32 ($239,960.21). Insiders own 1.45% of the company’s stock.
About MaxCyte
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Featured Stories
- Five stocks we like better than MaxCyte
- What is a Death Cross in Stocks?
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Breakout Stocks: What They Are and How to Identify Them
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- What does consumer price index measure?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.